Genentech Will Market OSI Cancer Drug In U.S. Under Three-Way Deal
Genentech will market OSI Pharmaceuticals' anti-cancer drug OSI-774 in the U.S. under a three-way co-development and marketing deal between Genentech, Roche and OSI.
Genentech will market OSI Pharmaceuticals' anti-cancer drug OSI-774 in the U.S. under a three-way co-development and marketing deal between Genentech, Roche and OSI.